JP2019506408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506408A5 JP2019506408A5 JP2018539976A JP2018539976A JP2019506408A5 JP 2019506408 A5 JP2019506408 A5 JP 2019506408A5 JP 2018539976 A JP2018539976 A JP 2018539976A JP 2018539976 A JP2018539976 A JP 2018539976A JP 2019506408 A5 JP2019506408 A5 JP 2019506408A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- subject
- agent
- appendix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290202P | 2016-02-02 | 2016-02-02 | |
| US62/290,202 | 2016-02-02 | ||
| PCT/US2017/016120 WO2017136492A1 (en) | 2016-02-02 | 2017-02-02 | Use of cd24 proteins for treating leptin-deficient conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506408A JP2019506408A (ja) | 2019-03-07 |
| JP2019506408A5 true JP2019506408A5 (https=) | 2020-03-12 |
| JP6938835B2 JP6938835B2 (ja) | 2021-09-22 |
Family
ID=59500202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539976A Expired - Fee Related JP6938835B2 (ja) | 2016-02-02 | 2017-02-02 | レプチン欠乏状態を治療するためのｃｄ２４タンパク質の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10799558B2 (https=) |
| EP (1) | EP3411062B1 (https=) |
| JP (1) | JP6938835B2 (https=) |
| KR (1) | KR20180120145A (https=) |
| CN (1) | CN109069583B (https=) |
| CA (1) | CA3012466A1 (https=) |
| SG (1) | SG11201806338SA (https=) |
| WO (1) | WO2017136492A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11547741B2 (en) * | 2017-05-22 | 2023-01-10 | Oncoimmune, Inc. | Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies |
| JP2021523929A (ja) * | 2018-03-05 | 2021-09-09 | オンコイミューン， インコーポレイテッド | 後天性免疫不全症候群（ｈｉｖ／ａｉｄｓ）の治療のための可溶性ｃｄ２４の使用方法 |
| WO2019236474A1 (en) * | 2018-06-04 | 2019-12-12 | Oncoimmune, Inc. | Methods of use of cd24 for the prevention and treatment of leukemia relapse |
| EP3921338A4 (en) * | 2019-02-06 | 2022-11-23 | Oncoimmune Inc. | TARGETED CD24-SIGLEC INTERACTIONS TO TREAT AND PREVENT NON-ALCOHOLIC STEATOHEPATITIS |
| US20220000974A1 (en) * | 2019-02-06 | 2022-01-06 | Oncolmmune, Inc. | Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1267909B1 (en) * | 2000-03-29 | 2010-07-28 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive t cells |
| WO2004106495A2 (en) * | 2003-05-29 | 2004-12-09 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| DK2563385T3 (da) * | 2010-04-28 | 2017-11-06 | Oncoimmune Inc | Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis |
| SG11201401811WA (en) * | 2011-08-30 | 2014-09-26 | Amc Amsterdam | Method for preventing and/or treating insulin resistance |
| HK1214628A1 (zh) | 2012-11-05 | 2016-07-29 | Pronai Therapeutics, Inc. | 寡核苷酸癌症療法的給藥和施用 |
-
2017
- 2017-02-02 KR KR1020187022125A patent/KR20180120145A/ko not_active Ceased
- 2017-02-02 WO PCT/US2017/016120 patent/WO2017136492A1/en not_active Ceased
- 2017-02-02 US US16/074,726 patent/US10799558B2/en not_active Expired - Fee Related
- 2017-02-02 CA CA3012466A patent/CA3012466A1/en not_active Abandoned
- 2017-02-02 EP EP17748111.6A patent/EP3411062B1/en active Active
- 2017-02-02 JP JP2018539976A patent/JP6938835B2/ja not_active Expired - Fee Related
- 2017-02-02 CN CN201780008474.2A patent/CN109069583B/zh not_active Expired - Fee Related
- 2017-02-02 SG SG11201806338SA patent/SG11201806338SA/en unknown
-
2020
- 2020-10-12 US US17/067,929 patent/US20210162006A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506408A5 (https=) | ||
| US20240254185A1 (en) | Interleukin-2 variants and methods of uses thereof | |
| JP2013527168A5 (https=) | ||
| AU2012252153B2 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| JP2025163204A (ja) | アクチビンｉｉａ型受容体変異体を含む医薬組成物 | |
| JP2015500811A5 (https=) | ||
| JP2025138661A (ja) | Ｆｃｒｎ抗体およびその使用の方法 | |
| TW200908995A (en) | Antibody formulations | |
| CN109306015A (zh) | 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用 | |
| JP2017101068A5 (https=) | ||
| ES2926511T3 (es) | Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos | |
| ES2655941T3 (es) | Proteína de fusión | |
| AU2017205343A1 (en) | Self-crosslinking antibodies | |
| NO330221B1 (no) | Anvendelse av en antagonist for integrin <alfa>-4-subenheten for fremstilling av et medikament til behandling av fibrose | |
| WO2021217120A2 (en) | Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor | |
| CA2824805A1 (en) | Il-27 antagonists for treating inflammatory diseases | |
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2018201516A (ja) | Ｃｂ１受容体抗原結合タンパク質及びその使用 | |
| WO1997041229A1 (en) | Antibodies against interferon alpha/beta receptor | |
| WO2016019036A2 (en) | Recombinant collagen iv surrogates and uses thereof | |
| JP2011032188A (ja) | 融合蛋白質 | |
| JP5137818B2 (ja) | 関節リウマチの処置剤 | |
| TW202544038A (zh) | 用於治療甲狀腺眼病的方法 | |
| US12540187B2 (en) | Method of treating vascular eye and retinal diseases by administration of anti-Neuropilin 1A antibodies | |
| WO2000023477A9 (en) | Immunoglobulin variants |